CTLA4 and cancer: In another monocentric retrospective study at Memorial Sloan Kettering Cancer Center of New York, Betof Warner et al. analyzed the clinical outcomes of 396 patients who interrupted therapy with anti-PD-1 or anti-PD-1/anti-CTLA-4 combination for all reasons, including disease progression (196 patients) and having at least 3 months of follow-up after discontinuation [25].